Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | CA2 | P00918 | 4/20 | 0.32 |
| ▸ | CA9 | Q16790 | 4/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14706960 | 0.81 | PTGS2 (0.46) | HDAC1HDAC6PTGS2KIF11 | |
| SCHEMBL19833060 | 0.80 | CA1 (0.37) | PTGS2KIF11CA1CA2CA9 | |
| SCHEMBL4136925 | 0.78 | HDAC1 (0.40) | HDAC1HDAC6PTGS2CA1CA2 | |
| SCHEMBL19833061 | 0.76 | EPAS1 (0.39) | PTGS2KIF11CA1CA9CA12 | |
| SCHEMBL21330942 | 0.76 | KMT2A (0.46) | PTGS2KIF11CA1CA2CA9 | |
| SCHEMBL17937375 | 0.75 | DRD1 (0.33) | PTGS2KIF11CA2DRD1 | |
| SCHEMBL26795602 | 0.75 | TSHR (0.35) | PTGS2 | |
| SCHEMBL26795603 | 0.75 | TSHR (0.35) | PTGS2 | |
| SCHEMBL603929 | 0.74 | CA2 (0.55) | PTGS2CA1CA2CA9CA12 | |
| SCHEMBL22396634 | 0.74 | HDAC1 (0.42) | HDAC1HDAC6PTGS2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028500-A1 | New Azabenzimidazole Derivatives as Agonists of the AMP-Activated Protein Kinase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028500-A1 | New Azabenzimidazole Derivatives as Agonists of the AMP-Activated Protein Kinase | PRKAB1, PRKAG1, PRKAB2 | HDAC1 524/4885HDAC6 1606/4885PTGS2 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.